Aflibercept-Related Sterile Inflammation
Within the first 3 months after approval of aflibercept (Eylea; Regeneron, Inc., Tarrytown, NY) by the US Food and Drug Administration on November 18, 2011, a cluster of injection-related sterile intraocular inflammation was reported, raising safety concerns. The American Society of Retina Specialists formed a Therapeutic Surveillance Subcommittee as an independent taskforce to monitor and report such events to the greater ophthalmology community.